logo
Conn College forum explores how social standing can bar access to basic freedoms

Conn College forum explores how social standing can bar access to basic freedoms

Yahoo11-02-2025

New London — A panel of local community leaders met Monday on the Connecticut College campus to discuss how entrenched policies and institutional biases can prevent marginalized residents from attaining even basic housing, educational and health needs.
That conversation touched on issues related to gentrification, success barriers and even the college's own relationship to the city.
The forum, 'From the Grassroots: (Un)Freedom and Community Advocacy,' was the first of four planned speaking events scheduled through March and sponsored by Conn College professors and the Eastern Connecticut Centers for Affordable Housing group.
Monday's forum in the college's Blaustein Humanities Center featured panelists Mayor Michael Passero; Cathy Zall, executive director of the New London Homeless Hospitality Center; David Morgan, president and chief executive officer of the New London-based Team Inc. anti-poverty group; Jennifer Paradis, executive director of Milford's Congregation Beth El; and Trina Charles, leader of the Step Up New London social justice organization.
The event focused on the concept of 'unfreedom, a term used by forum hosts to describe the state of marginalized people denied human rights despite them being ostensibly free.
Panelists, when asked to describe their experiences with both freedom and unfreedom, pulled examples from their work with the homeless, those without adequate health care options and the Black and brown community.
'We've never really had freedom; it's something we're still fighting for,' said Charles, whose group works to promote social and economic equity for the city's minority residents. 'But unfreedom means not having housing, or proper educational opportunities or proper health care.'
Zall said she considered herself fortunate to have butted up against few impediments in her career, while also being lucky enough to cultivate mentors and role models who enabled her to know her value. She said simply removing a barrier, such as those blocking an individual's access to housing or medical care, while a crucial start, isn't the endgame.
'It's also about building community and giving people a chance to feel they're part of something bigger,' Zall said.
Morgan called freedom the ability to reach a person's fullest potential, regardless of circumstances, though he noted the 'deep reality' of that process is fraught with challenges created by an individual's ZIP code and position in society's pecking order.
'They need a seat at the table, a voice, but in many cases these people are not even in the room, let alone at the table,' Morgan said.
Paradis said freedom is often taken for granted.
'(Freedom) is the ability to dream, to be curious about something and be able to pursue it relentlessly,' she said. 'But for too many, that ability to dream has been stripped away and life has become about survival. Or they're forced to lose a part of themselves when pursuing a dream — people are dying sooner because they don't have access to basic needs.'
Passero called New London a city of 'split personality' with a rich maritime history and pleasing geography marred by past instances of blatant segregation.
'We want a city where everyone has a fair shot,' he said, touting his administration's work in creating hundreds of new housing units and making the city a welcoming place for waves of incoming Electric Boat workers. 'It's a slow, hard process bridging that gap between freedom and unfreedom.'
A question from one of the 70 or so audience members on the dangers of gentrification prompted Passero to recall the 'white flight' decades earlier when affluent city residents pulled up stakes and moved to the suburbs.
'Many of them are returning now, hopefully with better attitudes,' he said, adding it's crucial to have a balance of residences — market-rate, affordable and everything in-between — to make a city viable.
Charles said the construction of several market-rate housing complexes in the city did amount to gentrification, in which the apartments were built to specifically attract higher-income tenants.
'And even then, they're not all rented out,' she said. 'We have 400 New London public school students classified as homeless and single mothers living in hotels.'
The speaking series is part of the (Un)Freedom Colloquium project, which aims to explore 'freedom, inequity and resistance in New London's past and present.' The forums in turn are part of a larger right-to-housing project that includes a planned traveling exhibition, a digital publication and community–based research. The three-year pilot program is being funded by a $500,000 public dialogue and research grant awarded to the college last month by the Mellon Foundation.
When students asked what practical steps they could take to address the issues of inequity, Zall said to "get proximate."
"Get out there at some level and get involved, she said.
j.penney@theday.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Black Kids Are 5 Times More Likely to Get Severe COVID. Now Vaccines Are Being Cut.
Black Kids Are 5 Times More Likely to Get Severe COVID. Now Vaccines Are Being Cut.

Yahoo

time11 minutes ago

  • Yahoo

Black Kids Are 5 Times More Likely to Get Severe COVID. Now Vaccines Are Being Cut.

The Trump administration has declared an end to COVID-19 vaccine recommendations for children and pregnant people, and health experts have a warning: This is a threat to Black communities. U.S. Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the Centers for Disease Control and Prevention, announced the decision on May 27 and said vaccine guidance would now focus solely on adults over 65 and those with high-risk conditions, effective immediately. By June 3, Dr. Lakshmi Panagiotakopoulos stepped down from her role helping lead the agency's COVID-19 vaccine advisory group, saying she could no longer support decisions that put pregnant people and children at risk. Before the changes took effect, COVID-19 vaccines were recommended for anyone 6 months and older. Kennedy did not offer a scientific rationale for the new recommendations. For Black Americans, the policy shifts are more than bureaucratic changes, according to Oni Blackstock, a physician and founder of Health Justice, a racial and health equity consulting practice. 'These new guidelines don't exist in a vacuum,' she said. 'Limiting booster eligibility risks further compromising the already fragile health status of many Black Americans.' Black Americans are 1.5 times more likely to contract COVID-19 and four times more likely to be hospitalized, according to the Centers for Medicare & Medicaid Services. Research from the Center for Primary Care at Harvard Medical School found that Black children are more than five times as likely to die from the virus. An estimated 165,000 to 220,000 Black Americans have died from COVID-19, according to data compiled by the APM Research Lab. According to a 2023 report from the U.S. Census Bureau, nearly 32% of Black Americans who contracted COVID-19 also experienced long COVID symptoms. The U.S. Food and Drug Administration cited a lack of evidence that annual boosters are needed by healthy, low-risk adults. However, Blackstock, a primary care and HIV physician, said the policy change marks a significant departure from past years when vaccines were broadly recommended and federally funded. 'This contradicts recent CDC data showing that the 2024–2025 boosters benefit people 18 years and older, especially early after vaccination,' she added. Blackstock noted that many Black Americans already struggle with health care access due to systemic barriers like a lack of insurance and residential segregation. 'When these combine with more restrictive vaccine guidelines,' she said, 'it becomes even harder for Black Americans to get boosters and worsens existing health disparities.' These barriers also deepen historic mistrust in health care, said Jerry Abraham, a family and community medicine physician. Abraham, who is director of the CDU-KEDREN Mobile Street Medicine program in Los Angeles, said the history of medical racism and continued treatment disparities fuel skepticism toward public health. Even as boosters offer real benefits, he said, many remain hesitant or disconnected from resources that ensure protection. 'If children and pregnant women are no longer recommended for vaccination, will grandma still go to CVS and get it herself?' he said. Abraham added that in an era where health care professionals can no longer trust the updated guidelines from federal agencies, it's deeply concerning and a reminder that Black communities must once again rely on themselves. For answers about what comes next, read on. Aisha Harris, a family medicine physician in Flint, Michigan, told Capital B that limiting access to COVID-19 vaccines for healthy adults exposes high-risk groups like seniors and those who are immunocompromised. 'Reduced protection in healthy people increases their risk of being infected by COVID and of being a carrier,' said Harris, who owns the direct primary care clinic Harris Family Medicine. 'When more people are contagious, with or without symptoms, they have a higher chance of infecting others around them, including in their household or those they are taking care of as caregivers.' She warned this undermines community immunity. Without widespread coverage, even eligible groups face elevated risks. FDA officials say the new approach mirrors those taken by Australia and several European nations that limit vaccines to older or high-risk adults. But some critics argue the shift ignores U.S. disparities and bypasses standard CDC procedures. You can pay out of pocket, but it could cost up to $200. If the CDC doesn't recommend vaccines, Abraham said health plans are much less likely to cover them, since insurers typically follow CDC guidance. Yes, COVID-19 vaccines have already undergone extensive clinical trials before being authorized for public use. The FDA says it will require longer clinical trials before approving updated shots for healthy kids and adults, with studies lasting at least six months, likely delaying fall approvals. The CDC's vaccine advisory committee is expected to vote on fall vaccine recommendations in late June, but it's unclear how much influence it will have over the newly announced changes. High-risk conditions for COVID-19 vaccine eligibility generally include chronic kidney disease, chronic lung diseases, asthma, diabetes, immunocompromised states (from cancer treatment, organ transplant, HIV, etc.), heart conditions, Alzheimer's disease, obesity, sickle cell disease, smoking, and stroke or cerebrovascular disease. Yes. Studies show COVID-19 vaccination, including boosters, reduces the risk of severe illness and may lower the chances of developing long COVID symptoms after infection. The post Black Kids Are 5 Times More Likely to Get Severe COVID. Now Vaccines Are Being Cut. appeared first on Capital B News.

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Yahoo

time23 minutes ago

  • Yahoo

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile with no safety signals. 'We are excited by these impressive results from MET-233i, which demonstrate exceptional efficacy with no safety signals, and enable the potential first monthly multi-NuSH combination,' said Steve Marso, M.D., Chief Medical Officer of Metsera. 'We observed five-week body weight loss comparable to that of leading GLP-1-based medicines, and we identified efficacious starting doses with placebo-like tolerability. These data position MET-233i as a potential best-in-class amylin and support a category-leading profile in combination with MET-097i.' The randomized, placebo-controlled, double-blind Phase 1 trial was designed to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous MET-233i in 80 participants with overweight or obesity without type 2 diabetes. MET-233i was evaluated at single doses from 0.15 mg to 2.4 mg, and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration. The trial population was broadly balanced in gender between MET-233i and placebo and had a mean baseline body mass index of approximately 32. Topline results from the Phase 1 trial include: Dose-linear pharmacokinetics with an observed half-life of 19 days from dose to 50% of Cmax. This represents the most durable pharmacokinetic profile of any known amylin analog and supports the potential for once-monthly dosing with simplified titration. MET-233i's exposure profile after multiple doses matched that of MET-097i, supporting combinability as a potential first-in-category once-monthly multi-NuSH combination. These data further substantiate HALO™, Metsera's proprietary, novel peptide stabilization and lipidation platform technology. Body weight loss up to 8.4%. Body weight loss was dose-dependent, ranging up to a placebo-subtracted mean of 8.4% at Day 36 after five weekly doses of 1.2 mg, with individual responses as high as 10.2%. In the single ascending dose (SAD) portion of the trial, substantial weight loss was maintained more than four weeks after dosing, supported by the ultra-long pharmacokinetics observed for MET-233i. Favorable tolerability results. Gastrointestinal adverse events in the multiple ascending dose (MAD) portion of the trial were all mild, dose-dependent, and primarily confined to the first week of dosing, implying rapid onset of tolerance despite a three-fold accumulation of exposure over five weeks. Anticipated starting doses of 0.15 mg and 0.3 mg demonstrated tolerability results comparable to placebo in both the SAD and the MAD portions of the trial. No safety signals. There were no severe or serious adverse events observed in the SAD or MAD portion of the trial to date. 'Amylin agonism has emerged as a central therapeutic mechanism for metabolic diseases, but candidates in development have been limited to weekly dosing,' said Professor Carel le Roux, Director of the Metabolic Medicine Group and Chair in Experimental Pathology at University College Dublin. 'The durability and efficacy of MET-233i in this trial, along with its combinability with Metsera's GLP-1 RA, make it the potential first monthly multi-NuSH combination candidate for patients seeking greater levels of well-tolerated weight loss with a more convenient dosing schedule.'Next StepsBased on these positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i: An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025. Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to twelve weeks, with topline data expected by year-end 2025 or early 2026. The Company also expects to report topline clinical data from its ultra-long acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025. We anticipate that MET-034i will be the third peptide engineered with Metsera's HALO™ platform to enter clinical Call and Webcast InformationMetsera will host a conference call and webcast today, June 9, 2025, at 8:00 A.M. Eastern Time to discuss the Phase 1 clinical trial of MET-233i. A live webcast of the call and a replay will be available on the Events page in the Investors & News section of the Metsera website at To access the call by phone, participants should visit this link to receive dial-in details: About MET-233i MET-233i is an ultra-long acting, subcutaneously injectable monthly amylin analog engineered for class-leading durability, potency, and combinability in solution with Metsera's fully-biased, ultra-long acting GLP-1 RA candidate MET-097i, with matched solubility parameters and observed half-lives. MET-233i is being explored in clinical studies as a monotherapy and in combination with MET-097i. Metsera is developing the combination of MET-233i and MET-097i via the FDA biologic pathway with the intent to pursue the combination's regulatory approval in the United States under a Metsera's HALO™ peptide stabilization and lipidation platformHALO™ is Metsera's novel peptide stabilization and lipidation platform technology that enables peptides to bind simultaneously to albumin and to a drug target, designed to facilitate a half-life approaching that of albumin and exceeding that of other NuSH peptides. This ultra-long half-life may enable monthly dosing, improved tolerability, and improved Metsera, is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the timelines, design and results of the Company's clinical trials and data releases; the Company's product candidate pipeline and milestone events; potential benefits of treatment with the Company's product candidates; and anticipated market opportunity and strategy. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, our limited operating history; our ability to generate revenue or become profitable; failure to obtain additional capital when needed on acceptable terms or at all; raising additional capital may cause dilution to our stockholders or require us to relinquish rights to our technologies or product candidates; our dependence on the success of our product candidates; risks associated with preclinical and clinical development; difficulties or delays in the commencement or completion, or the termination or suspension, of clinical trials; our ability to timely enroll patients in our clinical trials; if our current or future product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with the regulatory approval processes of the FDA and comparable foreign authorities; risks associated with conducting clinical trials and preclinical studies outside of the United States; our reliance on third parties to conduct clinical trials and preclinical studies; our reliance on third parties for the manufacture and shipping of our product candidates; risks associated with our license and collaboration agreements and future strategic alliances; significant competition in our industry; product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated; our success is dependent on our ability to attract and retain highly qualified management and other clinical and scientific personal; if we or our licensors are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or future product candidates or technology; risks associated with our common stock and the other important factors discussed under the caption 'Risk Factors' in its filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which are accessible on the SEC's website at and the Investors section of the Company's website at Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company's views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Contact:Jono EmmettMetseramedia@

Prime Healthcare cutting 100 jobs across its Illinois facilities, months after acquiring hospitals from Ascension
Prime Healthcare cutting 100 jobs across its Illinois facilities, months after acquiring hospitals from Ascension

Chicago Tribune

time24 minutes ago

  • Chicago Tribune

Prime Healthcare cutting 100 jobs across its Illinois facilities, months after acquiring hospitals from Ascension

Prime Healthcare, which bought eight Illinois hospitals earlier this year, is eliminating more than 100 jobs, the hospital system confirmed Monday. Prime made most of the reductions Friday, and will continue cutting other jobs through July. 'As we continue to offer and create opportunities, we are also evaluating alignment with best practices and support from our national and regional teams,' Prime said in a statement. 'Through this process, there is a small number of positions that are duplicated or not aligned with the care model and service line offerings – most of them not directly providing patient care – that will be consolidated.' None of the affected jobs are union positions, according to Prime. Prime hired 13,000 workers from Ascension when it bought the hospitals from that health system, and has created nearly 1,000 new jobs since the acquisition. The job cuts represent less than 1% of the combined 14,000 employees, according to the statement. 'Importantly, these efforts will not affect the quality of care we deliver to the communities we serve and in fact will help expand best practices from across the nation,' Prime said in the statement. 'All decisions made at our Illinois facilities are guided by our mission to improve quality, strengthen care delivery, preserve access in underserved areas and ensure long-term sustainability.' The California-based Prime bought the Illinois hospitals for more than $370 million in March. Six of the hospitals sold to Prime changed from being nonprofit hospitals to for-profit hospitals as part of the sale. Hospitals that were sold include St. Mary's Hospital in Kankakee, Holy Family Medical Center in Des Plaines, Resurrection Medical Center in Chicago, St. Francis Hospital in Evanston, St. Joseph Medical Center in Joliet, St. Joseph Hospital in Elgin, Mercy Medical Center in Aurora and St. Mary of Nazareth Hospital in Chicago. The job cuts are the latest in a string of changes Prime has made since closing the deal, drawing criticism from elected officials and a nurses' union. Prime announced in April that it planned to suspend inpatient pediatric care at St. Joseph Medical Center in Joliet, saying at the time that the unit had been averaging less than one patient a day, while the need for other services such as advanced surgical, neurosurgical and spinal care had grown. The Illinois Nurses Association condemned the move arguing it would hurt the community, which only has one hospital. Also, Mercy Medical Center in Aurora lost its designation in April as a Level II trauma center. Prime also suspended obstetrical services at St. Mary's in Kankakee after the hospital's 'nearly sole obstetrics physician' retired, and because of low demand, Prime has said. Sen. Dick Durbin and Tammy Duckworth sent a letter to Prime's chairman, founder and CEO Dr. Prem Reddy, in May expressing concern about those changes and asking Prime to elaborate on the reasons behind them and its future plans for the hospitals. Prime responded to that letter last week, emphasizing its mission of turning around struggling community hospitals across the country. Prime said that before it bought the hospitals in Illinois they were losing about $200 million a year. Prime said maintaining services with low patient demand is not sustainable, nor good for the quality of care. Prime also told the senators it plans to expand behavioral health care services for seniors at its Illinois facilities. In its statement Monday, Prime said it has started fulfilling a previously stated commitment to invest $250 million across the Illinois hospitals. Prime said those affected by the job cuts are invited to apply for any of the more than 900 open positions across its Illinois facilities. The job cuts were first reported by the Herald News.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store